Skip to main content

Ivers-Read Gillian C's Form 4 filing

Clovis Oncology, Inc. (CLVS) · filed May 3, 2022

Accession no.
0000899243-22-016297
Filed
May 3, 2022
Trade date
May 1-2, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $7.35K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Ivers-Read Gillian CCIK 0001268304Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 1, 2022Common StockMOption exerciseAcquired+3,749–F1–277,891Direct
May 2, 2022Common StockSSaleDisposed−1,671$1.97F3−$3,291.87276,220Direct
May 1, 2022Common StockMOption exerciseAcquired+4,625–F1–280,845Direct
May 2, 2022Common StockSSaleDisposed−2,062$1.97F3−$4,062.14278,783Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 1, 2022Common StockMOption exerciseDisposed−3,749$0.00$011,248Direct
May 1, 2022Common StockMOption exerciseDisposed−4,625$0.00$032,375Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each Restricted Stock Unit represents the right to receive one share of Common Stock.

Referenced by the price of 2 transactions in Table I.

F3

This transaction was executed in multiple trades at prices ranging from $1.950 to $1.970. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 2 transactions in Table I.

Remarks

Executive Vice President of Technical Operations and Chief Regulatory Officer

Read the full filing on SEC EDGAR (opens in a new tab)